NCT07397429 Group Therapy Using the "I-Reconstruction" Psychotherapy Method to Reduce Anxiety Levels
| NCT ID | NCT07397429 |
| Status | Recruiting |
| Phase | — |
| Sponsor | International Association Psychosomatics And Health Therapy |
| Condition | Anxiety |
| Study Type | INTERVENTIONAL |
| Enrollment | 36 participants |
| Start Date | 2026-03-02 |
| Primary Completion | 2027-05-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 36 participants in total. It began in 2026-03-02 with a primary completion date of 2027-05-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Brief Summary of the Study The aim of this clinical trial is to find out if the group therapy method "Self-Reconstruction" helps to reduce anxiety in adults. The researchers want to see if the participants' emotional state becomes more stable after completing the course. The main questions that this study aims to answer are: Do people's anxiety levels decrease after taking the course of "I-Reconstruction" classes? Do the positive effects of the classes persist 3, 6 and 12 months after they finish? Do the participants' quality of life and ability to enjoy life improve? The researchers will compare a group of people who attend the therapy classes with a group of people who receive usual care to see if the new method is more effective. Participants will: Participate in 10 online group meetings once a week. Do simple breathing and movement exercises to calm the body and emotions. Discuss your feelings and desires with a professional in a safe group. Complete questionnaires about your condition at the beginning, during, and after the study.
Eligibility Criteria
Inclusion Criteria: Age between 18 and 55 years (inclusive). Clinically significant level of anxiety according to the Beck Anxiety Inventory (BAI) ≥ 9 points. Anxiety subscale score on the Hospital Anxiety and Depression Scale (HADS-A) ≥ 11 points. Significant level of preverbal trauma according to the "Diagnostics of Preverbal Dysregulation" (DPD, T. Pavlenko) questionnaire: total score ≥ 16. Specific subscale scores in DPD: "Desire" ≥ 5, "Satisfaction" ≥ 5, and "Possession" (Obsession) ≥ 6 points. Presence of internal conflicts according to the "Internal Conflict Test" (ICT) ≥ 1 point on the skin tissue measurement scale. Willingness to comply with the study protocol and the online therapy format. Exclusion Criteria: Current participation in any other psychotherapy during the study. Use of any psychotropic medications within the last 30 days (antidepressants, tranquilizers, neuroleptics, mood stabilizers). Diagnosed severe mental disorders (according to ICD-10/DSM-5) requiring specialized psychiatric care or inpatient treatment. Presence of acute suicidal risk. Substance abuse (alcoholism, drug addiction). Failure to meet any of the threshold values specified in the inclusion criteria.
Contact & Investigator
Tetiana Pavlenko
PRINCIPAL INVESTIGATOR
International Association of Psychosomatics and Health Therapy
Frequently Asked Questions
Who can join the NCT07397429 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying Anxiety. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07397429 currently recruiting?
Yes, NCT07397429 is actively recruiting participants. Contact the research team at tanjapavlenko28223@gmail.com for enrollment information.
Where is the NCT07397429 trial being conducted?
This trial is being conducted at Kyiv, Ukraine.
Who is sponsoring the NCT07397429 clinical trial?
NCT07397429 is sponsored by International Association Psychosomatics And Health Therapy. The principal investigator is Tetiana Pavlenko at International Association of Psychosomatics and Health Therapy. The trial plans to enroll 36 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.